Randomized Controlled Trial

. 2019 May 10;17(1):83.

doi: 10.1186/s12955-019-1135-8.

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

Yuan Shi¹, Jennifer Thompson^{2

3}, A Sarah Walker², Nicholas I Paton^{2

4}, Yin Bun Cheung^{5

6}; EARNEST Trial Team

Collaborators, Affiliations

Collaborators

EARNEST Trial Team:
E Agweng, P Awio, G Bakeinyaga, C Isabirye, U Kabuga, S Kasuswa, M Katuramu, C Kityo, F Kiweewa, H Kyomugisha, E Lutalo, P Mugyenyi, D Mulima, H Musana, G Musitwa, V Musiime, M Ndigendawan, H Namata, J Nkalubo, P Ocitti Labejja, P Okello, P Olal, G Pimundu, P Segonga, F Ssali, Z Tamale, D Tumukunde, W Namala, R Byaruhanga, J Kayiwa, J Tukamushaba, S Abunyang, D Eram, O Denis, R Lwalanda, L Mugarura, J Namusanje, I Nankya, E Ndashimye, E Nabulime, D Mulima, O Senfuma, G Bihabwa, E Buluma, P Easterbrook, A Elbireer, A Kambugu, D Kamya, M Katwere, R Kiggundu, C Komujuni, E Laker, E Lubwama, I Mambule, J Matovu, A Nakajubi, J Nakku, R Nalumenya, L Namuyimbwa, F Semitala, B Wandera, J Wanyama, H Mugerwa, A Lugemwa, E Ninsiima, T Ssenkindu, S Mwebe, L Atwine, H William, C Katemba, S Abunyang, M Acaku, P Ssebutinde, H Kitizo, J Kukundakwe, M Naluguza, K Ssegawa, F Nsibuka, P Tuhirirwe, M Fortunate, J Acen, J Achidri, A Amone, M Chamai, J Ditai, M Kemigisa, M Kiconco, C Matama, D Mbanza, F Nambaziira, M Owor Odoi, A Rweyora, G Tumwebaze, H Kalanzi, J Katabaazi, A Kiyingi, M Mbidde, M Mugenyi, R Mwebaze, P Okong, I Senoga, M Abwola, D Baliruno, J Bwomezi, A Kasede, M Mudoola, R Namisi, F Ssennono, S Tuhirwe, G Abongomera, G Amone, J Abach, I Aciro, B Arach, P Kidega, J Omongin, E Ocung, W Odong, A Philliam, H Alima, B Ahimbisibwe, E Atuhaire, F Atukunda, G Bekusike, A Bulegyeya, D Kahatano, S Kamukama, J Kyoshabire, A Nassali, A Mbonye, T M Naturinda, A Nshabohurira, H Ntawiha, A Rogers, M Tibyasa, S Kiirya, D Atwongyeire, A Nankya, C Draleku, D Nakiboneka, D Odoch, L Lakidi, R Ruganda, R Abiriga, M Mulindwa, F Balmoi, S Kafuma, E Moriku, J Hakim, A Reid, E Chidziva, G Musoro, C Warambwa, G Tinago, S Mutsai, M Phiri, S Mudzingwa, T Bafana, V Masore, C Moyo, R Nhema, S Chitongo, Robert Heyderman, Lucky Kabanga, Symon Kaunda, Aubrey Kudzala, Linly Lifa, Jane Mallewa, Mike Moore, Chrissie Mtali, George Musowa, Grace Mwimaniwa, Rosemary Sikwese, Joep van Oosterhout, Milton Ziwoya, H Chimbaka, B Chitete, S Kamanga, T Kayinga E Makwakwa, R Mbiya, M Mlenga, T Mphande, C Mtika, G Mushani, O Ndhlovu, M Ngonga, I Nkhana, R Nyirenda, P Cheruiyot, C Kwobah, W Lokitala Ekiru, M Mokaya, A Mudogo, A Nzioka, A Siika, M Tanui, S Wachira, K Wools-Kaloustian, P Alipalli, E Chikatula, J Kipaila, I Kunda, S Lakhi, J Malama, W Mufwambi, L Mulenga, P Mwaba, E Mwamba, A Mweemba, M Namfukwe, E Kerukadho, B Ngwatu, J Birungi, N Paton, J Boles, A Burke, L Castle, S Ghuman, L Kendall, A Hoppe, S Tebbs, M Thomason, J Thompson, S Walker, J Whittle, H Wilkes, N Young, C Kapuya, F Kyomuhendo, D Kyakundi, N Mkandawire, S Mulambo, S Senyonjo, B Angus, A Arenas-Pinto, A Palfreeman, F Post, D Ishola, J Arribas, R Colebunders, M Floridia, M Giuliano, P Mallon, P Walsh, M De Rosa, E Rinaldi, I Weller, C Gilks, J Hakim, A Kangewende, S Lakhi, E Luyirika, F Miiro, P Mwamba, P Mugyenyi, S Ojoo, N Paton, S Phiri, J van Oosterhout, A Siika, S Walker, A Wapakabulo, T Peto, N French, J Matenga, G Cloherty, J van Wyk, M Norton, S Lehrman, P Lamba, K Malik, J Rooney, W Snowden, J Villacian

Affiliations

¹ Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.
² Medical Research Council Clinical Trials Unit, University College London, London, UK.
³ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
⁴ Department of Infectious Disease, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁵ Program in Health Services & System Research and Center for Quantitative Medicine, Duke-NUS Medical School, Level 6, Academia, Singapore, Singapore. yinbun.cheung@duke-nus.edu.sg.
⁶ Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland. yinbun.cheung@duke-nus.edu.sg.

PMID: 31077251
PMCID: PMC6511158
DOI: 10.1186/s12955-019-1135-8

Randomized Controlled Trial

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

Yuan Shi et al. Health Qual Life Outcomes. 2019.

. 2019 May 10;17(1):83.

doi: 10.1186/s12955-019-1135-8.

Authors

Yuan Shi¹, Jennifer Thompson^{2

3}, A Sarah Walker², Nicholas I Paton^{2

4}, Yin Bun Cheung^{5

6}; EARNEST Trial Team

Collaborators

EARNEST Trial Team:
E Agweng, P Awio, G Bakeinyaga, C Isabirye, U Kabuga, S Kasuswa, M Katuramu, C Kityo, F Kiweewa, H Kyomugisha, E Lutalo, P Mugyenyi, D Mulima, H Musana, G Musitwa, V Musiime, M Ndigendawan, H Namata, J Nkalubo, P Ocitti Labejja, P Okello, P Olal, G Pimundu, P Segonga, F Ssali, Z Tamale, D Tumukunde, W Namala, R Byaruhanga, J Kayiwa, J Tukamushaba, S Abunyang, D Eram, O Denis, R Lwalanda, L Mugarura, J Namusanje, I Nankya, E Ndashimye, E Nabulime, D Mulima, O Senfuma, G Bihabwa, E Buluma, P Easterbrook, A Elbireer, A Kambugu, D Kamya, M Katwere, R Kiggundu, C Komujuni, E Laker, E Lubwama, I Mambule, J Matovu, A Nakajubi, J Nakku, R Nalumenya, L Namuyimbwa, F Semitala, B Wandera, J Wanyama, H Mugerwa, A Lugemwa, E Ninsiima, T Ssenkindu, S Mwebe, L Atwine, H William, C Katemba, S Abunyang, M Acaku, P Ssebutinde, H Kitizo, J Kukundakwe, M Naluguza, K Ssegawa, F Nsibuka, P Tuhirirwe, M Fortunate, J Acen, J Achidri, A Amone, M Chamai, J Ditai, M Kemigisa, M Kiconco, C Matama, D Mbanza, F Nambaziira, M Owor Odoi, A Rweyora, G Tumwebaze, H Kalanzi, J Katabaazi, A Kiyingi, M Mbidde, M Mugenyi, R Mwebaze, P Okong, I Senoga, M Abwola, D Baliruno, J Bwomezi, A Kasede, M Mudoola, R Namisi, F Ssennono, S Tuhirwe, G Abongomera, G Amone, J Abach, I Aciro, B Arach, P Kidega, J Omongin, E Ocung, W Odong, A Philliam, H Alima, B Ahimbisibwe, E Atuhaire, F Atukunda, G Bekusike, A Bulegyeya, D Kahatano, S Kamukama, J Kyoshabire, A Nassali, A Mbonye, T M Naturinda, A Nshabohurira, H Ntawiha, A Rogers, M Tibyasa, S Kiirya, D Atwongyeire, A Nankya, C Draleku, D Nakiboneka, D Odoch, L Lakidi, R Ruganda, R Abiriga, M Mulindwa, F Balmoi, S Kafuma, E Moriku, J Hakim, A Reid, E Chidziva, G Musoro, C Warambwa, G Tinago, S Mutsai, M Phiri, S Mudzingwa, T Bafana, V Masore, C Moyo, R Nhema, S Chitongo, Robert Heyderman, Lucky Kabanga, Symon Kaunda, Aubrey Kudzala, Linly Lifa, Jane Mallewa, Mike Moore, Chrissie Mtali, George Musowa, Grace Mwimaniwa, Rosemary Sikwese, Joep van Oosterhout, Milton Ziwoya, H Chimbaka, B Chitete, S Kamanga, T Kayinga E Makwakwa, R Mbiya, M Mlenga, T Mphande, C Mtika, G Mushani, O Ndhlovu, M Ngonga, I Nkhana, R Nyirenda, P Cheruiyot, C Kwobah, W Lokitala Ekiru, M Mokaya, A Mudogo, A Nzioka, A Siika, M Tanui, S Wachira, K Wools-Kaloustian, P Alipalli, E Chikatula, J Kipaila, I Kunda, S Lakhi, J Malama, W Mufwambi, L Mulenga, P Mwaba, E Mwamba, A Mweemba, M Namfukwe, E Kerukadho, B Ngwatu, J Birungi, N Paton, J Boles, A Burke, L Castle, S Ghuman, L Kendall, A Hoppe, S Tebbs, M Thomason, J Thompson, S Walker, J Whittle, H Wilkes, N Young, C Kapuya, F Kyomuhendo, D Kyakundi, N Mkandawire, S Mulambo, S Senyonjo, B Angus, A Arenas-Pinto, A Palfreeman, F Post, D Ishola, J Arribas, R Colebunders, M Floridia, M Giuliano, P Mallon, P Walsh, M De Rosa, E Rinaldi, I Weller, C Gilks, J Hakim, A Kangewende, S Lakhi, E Luyirika, F Miiro, P Mwamba, P Mugyenyi, S Ojoo, N Paton, S Phiri, J van Oosterhout, A Siika, S Walker, A Wapakabulo, T Peto, N French, J Matenga, G Cloherty, J van Wyk, M Norton, S Lehrman, P Lamba, K Malik, J Rooney, W Snowden, J Villacian

Affiliations

¹ Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.
² Medical Research Council Clinical Trials Unit, University College London, London, UK.
³ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
⁴ Department of Infectious Disease, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁵ Program in Health Services & System Research and Center for Quantitative Medicine, Duke-NUS Medical School, Level 6, Academia, Singapore, Singapore. yinbun.cheung@duke-nus.edu.sg.
⁶ Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland. yinbun.cheung@duke-nus.edu.sg.

PMID: 31077251
PMCID: PMC6511158
DOI: 10.1186/s12955-019-1135-8

Abstract

Background: Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile method (EPM), and a recently proposed method called Mean Rank Method (MRM).

Methods: This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421 participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate the mapping functions.

Results: In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar.

Conclusions: Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were comparable in terms of agreement with the observed utility values at the individual level. MRM had better performance at the group level in terms of describing the utility distribution.

Trial registration: NCT00988039 . Registered 30 September 2009.

Keywords: EQ-5D; Health utility; Mapping; Medical outcomes study HIV health survey.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This secondary analysis was approved by the National University of Singapore Institutional Review Board (S-17-017E). The trial protocol was approved by ethics committees in all participating countries and by the research ethics committee of the University College London, UK.

Informed consent was obtained from all individual participants or their caregivers, in the case of participants less than 18 years of age, included in the study. Patients below 18 years of age also gave assent.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

**Fig. 1**
Observed EQ-5D-3 L utility values and mean mapped values obtained from the mean rank method (MRM), equi-percentile method (EPM) and ordinary least square (OLS) in the 18 to 65 range of MOS-score. (With random jittering to avoid over-lapping of data points)

See this image and copyright information in PMC

References

1. Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes: Oxford University Press. 2015.
1. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727–1736. doi: 10.1007/s11136-011-9903-x. - DOI - PMC - PubMed
1. Horsman J, Furlong W, Feeny D, et al. The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54. doi: 10.1186/1477-7525-1-54. - DOI - PMC - PubMed
1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108. doi: 10.1097/00005650-199711000-00002. - DOI - PubMed
1. Fayers PM, Hays RD. Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health. 2014;17(2):261–265. doi: 10.1016/j.jval.2013.12.002. - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

Collaborators

Affiliations

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher’s Note

Figures

References

Publication types

MeSH terms

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical